Page last updated: 2024-10-16

adenine and Lymphoma, B-Cell, Marginal Zone

adenine has been researched along with Lymphoma, B-Cell, Marginal Zone in 11 studies

Lymphoma, B-Cell, Marginal Zone: Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.

Research Excerpts

ExcerptRelevanceReference
"Splenomegaly is a common finding in chronic hepatitis B infection."1.42Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma. ( Huits, RM; Koot, AW; Visscher, AP, 2015)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (54.55)24.3611
2020's5 (45.45)2.80

Authors

AuthorsStudies
Epperla, N2
Zhao, Q1
Chowdhury, SM1
Shea, L1
Moyo, TK1
Reddy, N1
Sheets, J1
Weiner, DM1
Geethakumari, PR1
Kandarpa, M1
Bruno, XJ1
Thomas, C1
Churnetski, MC1
Hsu, A1
Zurbriggen, L1
Tan, C1
Lindsey, K1
Maakaron, J1
Caimi, PF1
Torka, P1
Bello, C1
Ayyappan, S2
Karmali, R1
Kim, SH1
Kress, A1
Kothari, S1
Sawalha, Y1
Christian, B1
David, KA1
Greenwell, IB1
Janakiram, M1
Kenkre, VP1
Olszewski, AJ1
Cohen, JB1
Palmisiano, N1
Umyarova, E1
Wilcox, RA1
Awan, FT1
Alderuccio, JP1
Barta, SK1
Grover, NS1
Ghosh, N1
Bartlett, NL1
Herrera, AF1
Shouse, G1
Zhou, H1
Yang, L1
Dang, Q1
Huang, J1
Cheng, Y1
Zhang, Y1
Shi, W1
Furqan, F1
Watson, G1
Samaniego, F1
Fayad, LE1
Morrison, MW1
Thompson, PA1
Steiner, RE1
Chi, L1
Dabaja, B1
Pinnix, CC1
Neelapu, SS1
Nastoupil, LJ1
Strati, P1
de Jong, J1
Mitselos, A1
Jurczak, W1
Cordoba, R1
Panizo, C1
Wrobel, T1
Dlugosz-Danecka, M1
Jiao, J1
Sukbuntherng, J1
Ouellet, D1
Hellemans, P1
Noy, A2
de Vos, S2
Coleman, M2
Martin, P2
Flowers, CR2
Thieblemont, C3
Morschhauser, F2
Collins, GP2
Ma, S2
Peles, S2
Smith, SD1
Barrientos, JC2
Chong, E1
Wu, S1
Cheung, LW1
Kwei, K1
Hauns, B1
Arango-Hisijara, I1
Chen, R2
Zhang, L1
Nomie, K1
Zhang, H1
Bell, T1
Pham, L1
Kadri, S1
Segal, J1
Li, S1
Zhou, S1
Santos, D1
Richard, S1
Sharma, S1
Chen, W1
Oriabure, O1
Liu, Y1
Huang, S1
Guo, H1
Chen, Z1
Tao, W1
Li, C1
Wang, J2
Fang, B1
Li, L1
Badillo, M1
Ahmed, M1
Thirumurthi, S1
Huang, SY1
Shao, Y1
Lam, L1
Yi, Q1
Wang, YL1
Wang, M1
Shana'ah, AY1
Jones, D1
Christian, BA1
Maddocks, K1
Woyach, JA1
Koot, AW1
Visscher, AP1
Huits, RM1
Smith, S1
Smith, A1
Munneke, B1
Dimery, I1
Beaupre, DM1
Muñoz Bertrán, E1
Pérez Ceballos, E1
Gómez Espín, R1
Ortega González, I1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy[NCT03301207]Phase 125 participants (Actual)Interventional2017-10-20Completed
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma[NCT01980628]Phase 263 participants (Actual)Interventional2013-12-31Completed
Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647]Phase 24 participants (Actual)Interventional2020-11-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

DOR (Duration of Response)

The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause. (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

InterventionMonths (Median)
IbrutinibNA

ORR (Overall Response Rate)

"ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC).~Per Cheson:~CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites." (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

InterventionPercentage of Participants (Mean)
Single Arm, Intent to Treat Population46

Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction

"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction

InterventionParticipants (Count of Participants)
Ublituximab Only2

Number of Participants With Complete Response Rate (CR) at up to 12 Months Post MONO - Monotherapy: Ublituximab or Combotherapy: Ublituximab + Umbralisib.

"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction

InterventionParticipants (Count of Participants)
Ublituximab Only2
Ublituximab First, Then Ublituximab and Umbralisib2

Overall Response Rates (ORR) for Number of Participants

"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction

InterventionParticipants (Count of Participants)
Ublituximab Only2
Ublituximab First, Then Ublituximab and Umbralisib2

Reviews

2 reviews available for adenine and Lymphoma, B-Cell, Marginal Zone

ArticleYear
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
    Hematology. American Society of Hematology. Education Program, 2017, 12-08, Volume: 2017, Issue:1

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide

2017
[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
    Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:5

    Topics: Adenine; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody

2010

Trials

3 trials available for adenine and Lymphoma, B-Cell, Marginal Zone

ArticleYear
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
    Pharmacology research & perspectives, 2020, Volume: 8, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Bupropion; Contrace

2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
    Blood advances, 2020, 11-24, Volume: 4, Issue:22

    Topics: Adenine; Biomarkers; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence

2020
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
    Blood, 2017, 04-20, Volume: 129, Issue:16

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia; Antineoplastic

2017

Other Studies

6 other studies available for adenine and Lymphoma, B-Cell, Marginal Zone

ArticleYear
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
    Journal of hematology & oncology, 2022, 07-16, Volume: 15, Issue:1

    Topics: Adenine; Cohort Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence, Local; Piperi

2022
Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.
    Cancer biology & therapy, 2020, 04-02, Volume: 21, Issue:4

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosp

2020
Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:12

    Topics: Adenine; Central Nervous System; Humans; Lymphoma, B-Cell, Marginal Zone; Piperidines; Pyrazoles; Py

2020
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-01, Volume: 23, Issue:15

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Burkitt Lymphoma; Disease Models, Animal; Dru

2017
Resistance mechanism for ibrutinib in marginal zone lymphoma.
    Blood advances, 2019, 02-26, Volume: 3, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Bone Marrow; Drug Resistance, Neoplasm; Humans;

2019
Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma.
    Acta clinica Belgica, 2015, Volume: 70, Issue:4

    Topics: Adenine; Bone Marrow; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lymphom

2015